Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study.

Trial Profile

Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms SHIFT
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 01 Sep 2017 Results published in the Circulation: Heart Failure
    • 30 Aug 2017 Results of post hoc analysis assessing the effect of Ivabradine on all-cause and cardiovascular mortality amongst the subgroup of patients who were not prescribed a beta-blocker presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 10 Jan 2017 According to a Servier Canada media release dated 10 Jan 2017, Health Canada has issued a Notice of Compliance for LANCORA (ivabradine) in patients suffering from chronic heart failure. This approval is based on a complete clinical development program, including the SHIFT trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top